TP53 and lymphoma: Various gene products, as TP53, ATM, and NK-κB complexes, are known to be associated with radioresistance for lymphoma cells [26–30], and underlying gene mutations and expressions can potentially contribute to the interpatient variance in dose threshold needed for response.